A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
Status:
Completed
Trial end date:
2018-09-19
Target enrollment:
Participant gender:
Summary
This study determined the effects of different doses and dosing regimens of ESN364 on the
frequency and severity of hot flashes. The treatment was administered for 12 weeks to
postmenopausal women, aged 40 to 65, suffering at least 50 moderate to severe hot flashes per
week.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc. Ogeda S.A.